Gara Jalqabaatti › Myelofibrosis › Kansas

Qorannoo klinikaalii Myelofibrosis Kansas keessatti

Qorannoo 6 Myelofibrosis f Kansas keessatti hirmaatuu jiru.

Takkalaa qorannoo (Ingiliffa)

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Indian Creek Campus, Overland Park
fi 1 dabalataa

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT06661915

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

University of Kansas Medical Center, Kansas City

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT06343805

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

The University of Kansas Cancer Center, Fairway

Namoota walitti qabaa jiraSadarkaa jalqabaa 1Hojjettoota fayyaa simatamoo

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Cam-2026 · NCT06414681

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

The University of Kansas Cancer Center, Westwood

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Elb-2026 · NCT06034002

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

University of Kansas Medical Center, Westwood

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 hanga 66 · Saalaa hunda · Haaromfame 17-Bit-2026 · NCT06859424

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

University of Kansas Cancer Center - Westwood, Westwood

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2025 · NCT06479135

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.